1 |
|
Baseline Characteristics of LHON Subjects in the RESCUE and REVERSE Phase III Gene Therapy Trials | Mark Moster, Catherine Vignal, Nancy Newman, Alfredo Sadun, Patrick Yu-Wai-Man, Valerio Carelli, Thomas Klopstock, Adam Debusk, Robert Sergott, Molly Scannel Bryan, Jose-Alain Sahel, Barrett Katz, Scott Uretsky | RESCUE and REVERSE are Phase‑ III, randomized, multicenter, double‑masked, sham‑ controlled trials of rAAV2/2-ND4, an intravitreally injected gene therapy for treatment of ND4‑ LHON. RESCUE subjects had vision loss for ≤6 months and REVERSE subjects from >6 months up to 1 year. | 20180306_nanos_posters_161 |